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Background: Hepatic steatosis is increasing worldwide. Whether HIV and its associated metabolic perturbations exacerbate steatosis is unclear. Sex differences in adipose tissue distribution may also affect steatosis risk. We examined the contribution of HIV and sex to steatosis.
Methods: Using MRI and spectroscopy, visceral adipose tissue (VAT) and liver fat fraction (LFF) were measured in 121 HIV-infected and 107 uninfected men and women without viral hepatitis. Differences in LFF by HIV status and sex were evaluated using multivariable linear regression, adjusting for demographic, lifestyle, VAT, homeostasis model assessment-estimated insulin resistance, and HIV-related factors.
Results: HIV-infected women had lower LFF than uninfected women (demographicadjusted mean: 1.9 vs. 3.1%; P ¼ 0.028); LFF was similar in HIV-infected and uninfected men (4.6 vs. 4.1%; P ¼ 0.78). HIV-infected and uninfected women had less VAT than men (median: 139 and 161 vs. 201 cm 3 and 188 cm 3 , respectively). After adjustment, HIV-infected women had 34% [95% confidence interval (CI): À54%, À5.5%] lower LFF than uninfected women, whereas there was little difference in men (À5.5%; 95% CI: À26%, 21%). Among HIV-infected persons, greater VAT and homeostasis model assessment-estimated insulin resistance were associated with greater LFF. HIV-related factors (CD4 þ cell count, HIV RNA level, or antiretroviral therapy use) had little association with LFF. Although HIV-infected men had 81% (95% CI: 32%, 148%) greater LFF than HIV-infected women, the association was attenuated after multivariable adjustment (25%; 95% CI: À9.1%, 73%).
Conclusion: Contrary to expectation, HIV infection is not associated with greater steatosis compared with uninfected adults. It is possible that less fat is stored in the liver to maintain subcutaneous fat (which is reduced in HIV) and the effect is magnified in HIV-infected women, who also have less VAT.
Introduction
The advent of effective antiretroviral therapy (ART) has led to dramatic improvements in the life expectancy of HIV-infected persons; yet, HIV-infected persons remain at greater risk of death than HIV-uninfected persons because of the emergence of non-AIDS-related morbidity that may be accelerated in the setting of HIV infection [1] . Chronic liver disease is now a leading cause of non-AIDS-related death, representing 13% of all deaths in this patient population. Although coinfection with viral hepatitis is the primary cause of liver disease, hepatic steatosis is emerging as a major contributor [2] [3] [4] .
Steatosis, which is part of the spectrum of nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence [5] and is reported to range from 10 to 46% [6] [7] [8] in the general population, paralleling the rise in obesity and associated conditions, including insulin resistance and dyslipidemia [9] . NAFLD can progress to cirrhosis and its complications, including hepatocellular carcinoma in up to 20% of patients [10] . Steatosis is also reported in 14-54% of HIV-monoinfected adults in the modern era of ART [2] [3] [4] [11] [12] [13] [14] [15] . HIV-infected adults may be at particular risk because HIV-related perturbations in adipose tissue and insulin resistance are common [3, 4, 16] . However, few have examined the prevalence and factors associated with steatosis in HIV-monoinfected relative to uninfected persons.
Less is known about sex differences in the pathogenesis of steatosis in the setting of HIV infection. Studies evaluating the influence of sex on NAFLD in the general population have been conflicting [8, [17] [18] [19] [20] [21] [22] . Two studies showed that women had a higher prevalence than men [20, 21] . In one, steatosis was defined by an elevated alanine aminotransferase (ALT) in the absence of alcohol use. [21] The other found a greater risk of biopsy-proven nonalcoholic steatohepatitis in women with NAFLD compared with men [20] . By contrast, a study in the National Health and Nutrition Examination Survey found that men were more than two times as likely as women to have steatosis (defined by an elevated ALT in the absence of alcohol use) [19] . The Dallas Heart Study found that white men had a two-fold higher prevalence of steatosis measured by magnetic resonance spectroscopy (MRS) than white women, whereas sex differences were not observed in blacks and Hispanics [17] . A limitation in interpreting these findings is the different modalities used to measure NAFLD; liver biopsy is generally considered the clinical gold standard and MRS the noninvasive gold standard to measure steatosis. Furthermore, it is unclear if women were pre or postmenopausal in these studies; some studies have shown that the protective effect of estrogen on steatosis is lost following the menopausal transition [23] [24] [25] .
We evaluated the contributions of HIV and sex to steatosis, after adjustment for demographic, lifestyle, body composition, and metabolic factors using data collected from two ethnically diverse cohorts of HIV-infected and uninfected adults. Visceral adipose tissue (VAT) volume was measured using MRI and liver fat fraction (LFF) was calculated from MRS.
Methods

Study population
The Women's Interagency HIV Study (WIHS) is a multicenter prospective cohort study that enrolled a total of 4982 women (3678 HIV infected and 1304 HIV uninfected) between 1994 and 2015 from 11 US cities. Baseline sociodemographic characteristics and HIV risk factors were similar between HIV-infected and uninfected women [26, 27] . An institutional review board approved study protocols and consent forms, and each participant gave written informed consent. Every 6 months, participants complete a comprehensive physical examination, provide biological specimens, and complete an interviewer-administered questionnaire. In both studies, patients with evidence of hepatitis B surface antigenemia, prior HCV treatment, history of decompensated cirrhosis, metal in their body, or a wide abdominal girth that would not allow them to fit into the MRI scanner were excluded from enrollment. For our analysis, HCV-infected participants from both studies were excluded to examine the relationship of HIVand sex with steatosis in the absence of viral hepatitis infection.
Ascertainment of magnetic resonance spectroscopy-measured liver fat fraction MRS was performed on a 1.5 Tesla (T) whole body clinical scanner (General Electric Healthcare, Waukesha, Wisconsin, USA) from December 2003 to February 2010 and on a 3T whole body scanner (General Electric Healthcare) beginning in March 2010. Data collected from the 1.5T scanner were standardized to values collected from the 3T scanner. All VAHH participants were scanned using the same 3T scanner as used in WIHS participants. A time series of 128 (1.5T) or 64 (3T) acquisitions of spectra were obtained from an 8 cm 3 , single voxel region of tissue and were analyzed with motion correction and T2 relaxation time correction algorithms using a standardized MRS protocol [28] . The peak areas under the resonance frequencies of lipids and unsuppressed water were calculated for each participant and the LFF derived as the ratio of the total lipids measure to the total lipids and unsuppressed water measure. The LFF was then multiplied by 100 and expressed as a percentage. A mean interexamination coefficient of variation for MRS-measured LFF of 11.9% (range 2.8-20.3%) in a sample of nine controls confirmed its reproducibility. Steatosis was defined as a LFF at least 5%.
Ascertainment of body composition and metabolic factors VAT and abdominal subcutaneous adipose tissue were calculated as the mean volume (cm 3 ) of the visceral and subcutaneous compartments, respectively by MRI of the L2/3, L3/4, and L4/5 intervertebral disk levels. BMI was calculated from height and weight in kilogram per meter squared (kg/m 2 ). Leg fat mass (kg) was determined from dual-energy X-ray absorptiometry scan (Lunar Prodigy, Madison, Wisconsin, USA). The homeostasis model assessment-estimated insulin resistance [HOMA-IR; fasting insulin (mIU/ml) Â glucose (mg/dl)/405].
Covariates
Our primary predictors were HIV infection status (defined by prior documentation of a positive HIV enzyme immunoassay confirmed by western blot) and sex. Candidate covariates included sociodemographic factors (age, sex, race/ethnicity), menopausal status categorized by anti-Mullerian hormone (AMH) level into premenopause (AMH > 0.9 ng/ml), perimenopause (AMH < 0.9 ng/ml within the past 5 years), and postmenopause (AMH < 0.9 ng/ml for more than 5 years), lifestyle factors [history of IDU, alcohol use (none; > 0-7 drinks/week; 7-12 drinks/week; >12 drinks/ week); marijuana use (current vs. not current), smoking (current vs. not current)], body composition (waist circumference, waist-to-hip ratio, BMI, MRI-measured VAT volume, dual-energy X-ray absorptiometrymeasured leg fat amount), metabolic factors [diabetes mellitus diagnosis (defined by a confirmed elevated fasting glucose, elevated hemoglobin A1C, or self-report of antidiabetes medications) and HOMA-IR], and liverrelated factors [aspartate aminotransferase (AST) level, ALT level, albumin, and AST to platelet ratio index, a serum marker of fibrosis]. HIV-related factors included current CD4 þ , nadir CD4 þ , current HIV RNA, history of clinical AIDS, and current use of highly active ART and ART by class. Because VAT and subcutaneous adipose tissue were missing in 14% of participants, we used the Markov chain Monte Carlo method to impute missing covariates. We used multivariable linear regression with robust standard errors to evaluate the association of HIV and sex with LFF after adjustment for lifestyle, body composition, and metabolic factors. LFF was found to be right skewed and was therefore log transformed for analysis; results were back transformed to produce estimated percentage differences. We also used logistic regression to investigate the association of the same covariates with the presence of steatosis.
To determine whether HIV was independently associated with the LFF in women and men, we created multivariable models, which were initially stratified by sex and then pooled women and men and tested for HIV by sex interactions. We sequentially adjusted for sociodemographic factors and then lifestyle, body composition, and metabolic factors. We next constructed separate models stratified by HIV status to identify correlates of LFF within each group. A stepwise regression with P value of 0.10 or less was used for entry and retention; the candidate variables were selected based upon their hypothesized associations with steatosis. Age and race/ethnicity were retained in all models.
All analyses were performed using the SAS system, version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). Table 1 shows the demographic and clinical characteristics of the 87 women and 142 men by HIV status. On average, women were younger than men, and uninfected women were the youngest. Women were more likely than men to be of African-American race and Hispanic ethnicity and to report abstaining from alcohol. A greater proportion of HIV-infected women were postmenopausal compared with uninfected women. HIV-infected men and women also appeared more likely to report not currently smoking than HIV-uninfected men and women. All body composition parameters appeared lower in the HIV-infected men and women compared with the respective uninfected men and women, except for VAT in men. HIV-infected women had lower HOMA-IR than uninfected women, whereas HIVinfected men had greater HOMA-IR than uninfected men, though these associations did not reach statistical significance. Among the HIV-infected participants, men were more likely than women to have an undetectable HIV RNA level, to be on highly active ART, and have a history of clinical AIDS; both men and women had a median CD4 þ cell count more than 500 cells/ml.
Results
Cohort characteristics
Association of HIV with liver fat fraction in men and women
We first compared LFF in HIV-infected and uninfected participants, stratified by sex, with adjustment for age and race/ethnicity (Fig. 1) . HIV-infected women had a lower LFF relative to uninfected women (marginal adjusted mean: 1.9 vs. 3.1%; P ¼ 0.028). By contrast, LFF was similar in HIV-infected and uninfected men (4.6 vs. 4.1%; P ¼ 0.78).
We next performed multivariable adjustment to determine whether HIV infection was independently associated with differences in the LFF in men and women ( (CI):À56%, À4.5%] lower LFF than uninfected women. This difference remained statistically significant and changed little after adjustment for demographic, lifestyle and metabolic factors, and after additional adjustment for liver fibrosis severity using AST to platelet ratio index. By contrast, there was little difference in the LFF between HIV-infected and uninfected men in demographicadjusted (þ5.1%; P ¼ 0.78) or fully adjusted analysis (À5.3%; P ¼ 0.66). However, the HIV-by-sex interaction on LFF did not reach statistical significance (P ¼ 0.10 in the fully adjusted model).
Our results were similar when we examined the association of HIV with the presence of steatosis. Steatosis was present in 17% of the HIV-infected women, 33% of the uninfected women, 41% of the HIV-infected men, and 33% of the uninfected men. After adjustment for age and race/ethnicity, HIV-infected women had 82% lower odds of having steatosis compared with uninfected women (Table 3) . This difference persisted after adjustment for demographic, lifestyle and metabolic factors, and additional adjustment for liver fibrosis severity. By contrast, HIV-infected men had 20% higher odds of having steatosis compared with uninfected men in demographic-adjusted analysis, although the association was not statistically significant. We did observe a significant HIV-by-sex interaction after demographic adjustment (P ¼ 0.019), but not after adjustment for demographic, lifestyle, and metabolic factors (P ¼ 0.162) and additional adjustment for liver fibrosis severity (P ¼ 0.119).
Factors associated with liver fat fraction in the HIV-infected and uninfected groups
We next sought to identify factors associated with LFF in HIV-infected and uninfected persons (Table 4) . Among the HIV infected, factors associated with greater LFF in unadjusted analysis included male gender, greater VAT, greater HOMA-IR, higher ALT, and higher serum albumin, whereas African-American race was associated with lower LFF. HIV-related factors, including CD4 þ cell count (À9.8% per doubling of CD4 þ ; 95% CI: À26%, 9.4%), HIV RNA (À3.3% per doubling; 95% CI: À9.4%, 3.2%), or ART use (58.1%; 95% CI: À7.8%, 171.3%) had little association with LFF in unadjusted analysis and were therefore not included in the final model. After multivariable adjustment, greater VAT, greater HOMA-IR, and higher albumin remained independently associated with greater LFF, whereas the effect of male gender was attenuated (from 81 to 25%) and was no longer statistically significant.
Among the uninfected, factors associated with greater LFF in both unadjusted and adjusted analysis included greater VAT, greater HOMA-IR, and higher ALT. There was little difference in the LFF between uninfected men and women. Higher serum albumin was also associated with greater LFF after multivariable adjustment, although the association did not reach statistical significance.
Sensitivity analysis including only participants with complete data was also performed and all inferences remained the same. Among the HIV infected, greater VAT (51%; 95% CI: 24%, 83%), greater HOMA-IR (18%; 95% CI: 4.6%, 34%), and higher albumin (6.6%; 95% CI: 2.5%, 11%) remained independently associated with greater LFF. Among the HIV uninfected, greater VAT (62%; 95% CI: 37%, 92%), greater HOMA-IR (23%; 95% CI: 7.5%, 40%), and higher ALT (31%; 95% CI: 3.3%, 66%) remained independently associated. Similarly, higher albumin was also associated with greater LFF, but the association did not reach significance (5.4%; 95% CI: 0.2%, 11%).
Discussion
In our study of HIV-infected and uninfected adults, contrary to expectation, we found that HIV is not associated with more liver fat; instead, we found that HIVinfected women have less liver fat than uninfected women and there was little difference in the LFF between HIVinfected and uninfected men. Our findings highlight the importance of having an uninfected comparison group. Our study is also novel in that to our knowledge, no study has examined the association of HIV monoinfection with steatosis in women and none has examined sex differences in the association of HIV with steatosis. In the HIVinfected group, we found that men had an 81% greater LFF than women, but after adjustment for demographic, lifestyle, metabolic, and HIV-related factors, the association was attenuated but remained 25% greater than women. By contrast, there was little difference between men and women in the uninfected group. These findings suggest that HIV infection contributes to a sex difference in steatosis risk beyond CD4 immunosuppression, HIV viral replication, and antiretroviral exposure, which we adjusted for in our analysis. As expected, visceral adiposity and insulin resistance were strongly associated with greater liver fat in both groups.
We observed a high steatosis prevalence in HIV-infected men and women of 41 and 17%, respectively which is consistent with published reports in HIV-monoinfected adults [2] [3] [4] 12, 13, 29] . However, when compared with the uninfected group, we did not find that HIV infection was associated with greater steatosis. Our observations were unexpected but few studies have included an uninfected comparison group and none has used MRS, the noninvasive gold standard to estimate steatosis. One other study of HIV-infected and uninfected men used the less sensitive liver-to-spleen ratio measured by computed tomography to estimate steatosis [15] and also observed that HIV monoinfection was associated with less steatosis. That study hypothesized that HIV monoinfected men may have less steatosis because of more frequent physician encounters, allowing for better control of risk factors associated with fatty liver disease. Another explanation for the lower liver fat in HIV-infected persons could be that HIV infection is associated with subcutaneous fat loss [30, 31] and adipocyte apoptosis in vitro [32, 33] , leaving little excess fat or triglycerides to be stored in hepatocytes. We observed that both HIV-infected men and women had less abdominal and lower limb subcutaneous fat compared with uninfected men and women. It is noteworthy that compared with HIV-uninfected women, HIV-infected women were older and more likely to report being postmenopausal, which has been associated with increased metabolic perturbations because of the loss of the protective effect of estrogen in studies of HIVuninfected women; yet HIV-infected women still had less steatosis than HIV-uninfected women.
Interestingly, HIV-infected men appeared to have slightly greater VAT than uninfected men, whereas HIV-infected women had less VAT than uninfected women, which could partly explain why the difference in liver fat between HIV-infected and uninfected men was not as large as that observed between HIV-infected and uninfected women. Furthermore, HIV-infected men appeared to be less immunosuppressed and more likely to be virally suppressed than HIV-infected women, which in the modern ARTera may be more likely associated with normalization of fat to that of an uninfected group, especially in the visceral compartment. After adjusting for body composition and HIV-related factors, including degree of immunosuppression, viral replication, and ARTuse, HIV-infected men still had 25% more liver fat than HIV-infected women. By contrast, we did not observe that uninfected men had more liver fat than uninfected women contrary to prior reports [17] [18] [19] 21] . These findings suggest that the sex difference observed in HIV could be explained by other HIVassociated factors and markers such as microbial translocation and inflammation need examination.
As expected, visceral adiposity, insulin resistance, and higher ALT were associated with greater liver fat in HIVinfected and uninfected groups. In the HIV-infected group, however, the association of ALT was attenuated and no longer significantly associated after adjustment. Several studies in the general population have used ALTas a surrogate marker of steatosis [18, 19, 21] , but our finding in the HIV setting indicates that ALT may not be as strong a marker of steatosis. In the HIV-infected group, we also found a strong association of higher albumin levels with greater liver fat. Low albumin levels have been associated with mortality in HIV-infected adults and thus may be a possible marker of overall health status [34] . The association of higher albumin with liver fat suggests that liver fat in virally suppressed HIV-infected persons could be an indicator of being healthy. Whether the combination of steatosis and underlying HIV-associated liver injury are associated with progression to nonalcoholic steatohepatitis and fibrosis needs study.
Our study has some limitations. First, we examined the association of HIV, sex, and liver fat using a cross-sectional design. Second, although we pooled men and women in our analysis by HIV status because we did not observe an HIV by sex interaction, we acknowledge that the lack of an interaction may have been because of the relatively small sample size of men and women. We did not use the clinical gold standard of liver biopsy to measure liver fat, although MRS is considered the noninvasive gold standard to measure steatosis. However, because of the different timespan of data collection, some MRS data were collected on a 1.5T scanner and some on a 3T scanner, which could have biased our results. Nevertheless, data collected from the 1.5T scanner were standardized to values collected from the 3T scanner. Finally, as in all observational studies, there may have been residual or unmeasured confounders for which we were unable to control. For example, the timespan of enrollment into the VAHH and the WIHS substudy were different and could have contributed to the sex differences observed in the HIV-infected group. Many of our HIV-infected men were enrolled from a clinic setting, whereas women were originally enrolled from both clinic and nonclinical settings. However, after adjustment for demographic, lifestyle, body composition and metabolic factors, as well as indicators of receiving HIV care, we still observed that HIV-infected men had greater liver fat than HIV-infected women.
In summary, HIV-infected persons do not have greater MRS-measured liver fat than uninfected persons. Rather, HIV infection is associated with less liver fat in women, whereas HIV-infected and uninfected men show little difference in liver fat. Because HIV infection is associated with loss of subcutaneous fat, it is possible that there is less storage of fat in the liver to maintain subcutaneous fat. This reduction in liver fat may be enhanced in HIV-infected women, who also have lower amounts of VAT. Regardless of HIV status, visceral adiposity and insulin resistance were strongly associated with liver fat, suggesting that interventions recommended in national guidelines to reduce steatosis in the general population can be extended to the HIV population. Studies examining how HIV-associated adipose tissue changes and inflammation affect steatosis and its progression are needed.
